Klexane

Enoxaparin Sodium, the active ingredient in Klexane, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous, and haemodialysis use. It is employed to prevent and treat thromboembolic disorders effectively in at‑risk patients.

GNH USA supplies Klexane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable logistics for this critical anticoagulant.

Klexane, a low molecular weight heparin, is used in several thromboembolic conditions. - Deep vein thrombosis (post‑surgical): Prevents clot formation in patients after surgery. - Acute deep vein thrombosis: Treats existing clots to restore venous patency. - Pulmonary embolism: Facilitates clot resolution and reduces mortality in acute cases. - Haemodialysis: Prevents circuit clotting during renal replacement therapy. - Acute coronary syndromes: Provides antithrombotic protection in unstable angina or myocardial infarction.

Enoxaparin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site bruising: Localized discoloration at the injection site. - Minor bleeding: Nosebleeds, gum bleeding, or easy bruising. - Nausea: Transient gastrointestinal upset.

Serious or Rare Side Effects: - Major bleeding: Gastrointestinal, intracranial, or surgical site hemorrhage. - Thrombocytopenia: Heparin‑induced platelet count reduction. - Spinal/epidural hematoma: Bleeding in the spinal canal after neuraxial procedures.

When using Klexane, several precautions should be observed. - Renal impairment: Adjust dose or monitor anti‑Xa activity in patients with reduced kidney function. - Elderly patients: Increased bleeding risk; use lowest effective dose. - Concomitant anticoagulants: Avoid combining with other anticoagulants unless clinically justified. - Recent surgery or trauma: Assess bleeding risk before initiating therapy. - Pregnancy: Use only if potential benefit outweighs risk to the fetus. - Store below 25°C: Keep in original packaging, protect from moisture and light.

Enoxaparin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): Heightened risk of severe bleeding. - Antiplatelet agents (e.g., aspirin, clopidogrel): Additive anticoagulant effect increasing hemorrhage. - NSAIDs (e.g., ibuprofen, naproxen): Potentiate bleeding tendency.

Moderate Interactions (Monitor Closely): - Renal function modifiers (e.g., aminoglycosides): May alter enoxaparin clearance. - Thrombolytic therapy (e.g., alteplase): Combined effect can increase bleeding. - SSRIs or SNRIs: May modestly increase bleeding risk; monitor patient.